Clinic and genetic predictors in response to erenumab.
anti-CGRP antibodies
erenumab
predictors
treatment response
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
20
11
2021
received:
15
07
2021
accepted:
21
12
2021
pubmed:
30
12
2021
medline:
5
4
2022
entrez:
29
12
2021
Statut:
ppublish
Résumé
Erenumab (ERE) is the first anticalcitonin gene-related peptide receptor monoclonal antibody approved for migraine prevention. A proportion of patients do not adequately respond to ERE. Prospective multicenter study involving 110 migraine patients starting ERE 70 mg monthly. Baseline socio-demographics and migraine characteristics, including mean monthly migraine days (MMDs), migraine-related burden (MIDAS [Migraine Disability Assessment scale] and Headache Impact Test-6), and use of abortive medications, during 3 months before and after ERE start were collected. Real-time polymerase chain reaction was used to determine polymorphic variants of calcitonin receptor-like receptor and receptor activity-modifying protein-1 genes. Logistic regression models were used to identify independent predictors for 50% responder patients (50-RESP) and 75% responder patients (75-RESP). At month 3, MMDs decreased from 17.2 to 9.2 (p < 0.0001), 59/110 (53.6%) patients were 50-RESP, and 30/110 (27.3%) were 75-RESP. Age at migraine onset (odds ratio [OR] [95% confidence interval (95% CI)]: 1.062 [1.008-1.120], p = 0.024), number of failed preventive medications (0.753 [0.600-0.946], p = 0.015), and MIDAS score (1.011 [1.002-1.020], p = 0.017) were associated with 75-RESP. Among the genetic variants investigated, RAMP1 rs7590387 was found associated with a lower probability of being 75-RESP (per G allele OR [95% CI]: 0.53 [0.29-0.99], p = 0.048]), but this association did not survive adjustment for confounding clinical variables (per G allele, 0.55 [0.28-1.10], p = 0.09]). In this real-word study, treatment with ERE significantly reduced MMDs. The number of failed preventive medications, migraine burden, and age at migraine onset predicted response to ERE. Larger studies are required to confirm a possible role of RAMP1 rs7590387 as genetic predictor of ERE efficacy.
Sections du résumé
BACKGROUND AND PURPOSE
Erenumab (ERE) is the first anticalcitonin gene-related peptide receptor monoclonal antibody approved for migraine prevention. A proportion of patients do not adequately respond to ERE.
METHODS
Prospective multicenter study involving 110 migraine patients starting ERE 70 mg monthly. Baseline socio-demographics and migraine characteristics, including mean monthly migraine days (MMDs), migraine-related burden (MIDAS [Migraine Disability Assessment scale] and Headache Impact Test-6), and use of abortive medications, during 3 months before and after ERE start were collected. Real-time polymerase chain reaction was used to determine polymorphic variants of calcitonin receptor-like receptor and receptor activity-modifying protein-1 genes. Logistic regression models were used to identify independent predictors for 50% responder patients (50-RESP) and 75% responder patients (75-RESP).
RESULTS
At month 3, MMDs decreased from 17.2 to 9.2 (p < 0.0001), 59/110 (53.6%) patients were 50-RESP, and 30/110 (27.3%) were 75-RESP. Age at migraine onset (odds ratio [OR] [95% confidence interval (95% CI)]: 1.062 [1.008-1.120], p = 0.024), number of failed preventive medications (0.753 [0.600-0.946], p = 0.015), and MIDAS score (1.011 [1.002-1.020], p = 0.017) were associated with 75-RESP. Among the genetic variants investigated, RAMP1 rs7590387 was found associated with a lower probability of being 75-RESP (per G allele OR [95% CI]: 0.53 [0.29-0.99], p = 0.048]), but this association did not survive adjustment for confounding clinical variables (per G allele, 0.55 [0.28-1.10], p = 0.09]).
CONCLUSIONS
In this real-word study, treatment with ERE significantly reduced MMDs. The number of failed preventive medications, migraine burden, and age at migraine onset predicted response to ERE. Larger studies are required to confirm a possible role of RAMP1 rs7590387 as genetic predictor of ERE efficacy.
Identifiants
pubmed: 34965002
doi: 10.1111/ene.15236
pmc: PMC9306465
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
erenumab
I5I8VB78VT
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1209-1217Informations de copyright
© 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Ann Neurol. 1990 Aug;28(2):183-7
pubmed: 1699472
Ann Neurol. 1993 Jan;33(1):48-56
pubmed: 8388188
J Headache Pain. 2020 Jul 3;21(1):84
pubmed: 32620151
J Headache Pain. 2020 Jun 16;21(1):76
pubmed: 32546227
J Headache Pain. 2019 Oct 30;20(1):99
pubmed: 31666008
Lancet. 2018 Mar 31;391(10127):1315-1330
pubmed: 29523342
Cephalalgia. 2002 Feb;22(1):54-61
pubmed: 11993614
Headache. 2020 Nov;60(10):2555-2562
pubmed: 32990364
J Headache Pain. 2020 Jun 1;21(1):61
pubmed: 32487102
Nat Rev Neurol. 2010 Oct;6(10):573-82
pubmed: 20820195
Neurology. 2001;56(6 Suppl 1):S20-8
pubmed: 11294956
Gene. 2013 Feb 15;515(1):187-92
pubmed: 23237777
Headache. 2020 Jan;60(1):28-39
pubmed: 31811654
N Engl J Med. 2017 Nov 30;377(22):2123-2132
pubmed: 29171821
Headache. 2020 Oct;60(9):2014-2025
pubmed: 32920850
Lancet. 2018 Nov 24;392(10161):2280-2287
pubmed: 30360965
Lancet. 2019 Aug 10;394(10197):521-532
pubmed: 31395440
Headache. 2021 Feb;61(2):363-372
pubmed: 33337544
Headache. 2015 May;55(5):658-68
pubmed: 25881990
J Headache Pain. 2020 Apr 07;21(1):32
pubmed: 32264820
Eur J Neurol. 2022 Apr;29(4):1209-1217
pubmed: 34965002
Neurol Sci. 2020 Dec;41(Suppl 2):483-484
pubmed: 32860531
Neurotherapeutics. 2018 Apr;15(2):313-323
pubmed: 29671241
Cell Rep. 2020 Feb 11;30(6):1714-1723.e6
pubmed: 32049005
Lancet Neurol. 2017 Jun;16(6):425-434
pubmed: 28460892
J Headache Pain. 2020 Jun 9;21(1):69
pubmed: 32517693
Cephalalgia. 2018 May;38(6):1026-1037
pubmed: 29471679